Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:29 PM ET 8-K
Financial Results Amprius Technologies, Inc. AMPX

Amprius Technologies Financial Results

Amprius Technologies reported record Q3 2026 revenue of $39.1 million, an 83% year-over-year increase driven by strong demand in drone, aviation, and defense markets. The company improved its GAAP net loss to $3.5 million and raised its full-year 2026 revenue outlook to $145 million.

Term
Q3 2026

“Our third quarter results demonstrate the strength of our company’s technology leadership and our ability to convert growing customer demand into meaningful financial performance. We delivered record revenue, as we continued to deepen our relationships with customers across the drone, aviation, defense, and advanced mobility markets.”

Tom Stepien, CEO
4:29 PM ET 8-K
Financial Results Quicklogic Corp QUIK

Quicklogic Financial Results

QuickLogic reported fiscal third quarter 2026 revenue of $5.1 million, a 153% increase year-over-year, driven by strong growth in new product revenue. The company reported a GAAP net loss of $2.2 million ($0.12 per share) and highlighted a recent six-figure eFPGA design win in the automotive industrial sector.

Term
Q3 2026

“Our recent automotive and industrial design win is a strong validation of our eFPGA technology. Combined with our latest eFPGA Hard IP advancements and continued progress on the U.S. strategic radiation-hardened FPGA program, we are building momentum across key areas of our business and anticipate a strong finish to the year.”

Brian Faith, CEO of QuickLogic
4:29 PM ET 8-K
Capital Raise Viper Energy, Inc. VNOM

Viper Energy Capital Raise

Viper Energy and its subsidiary VNOM Holding Company LLC adopted a distribution reinvestment plan (OpCo DRIP) allowing OpCo Unit holders to reinvest cash distributions into newly issued units. Participating holders, including Diamondback Energy, Inc., will receive one share of Class B common stock for each OpCo Unit issued, with the total issuance capped at approximately 72.2 million units.

Counterparty
Diamondback Energy, Inc.
4:28 PM ET Form 4
Insider Selling Motorola Solutions, Inc. MSI

Motorola Solutions EVP and CFO Jason J. Winkler Sells $8.93M of Stock

Jason J. Winkler, EVP and CFO, sold 17,161 shares of Motorola Solutions, Inc. at $513.00 to $529.12 a share (average $520.13) in 3 transactions, worth $8.93M in total between Nov 6, 2026 and Nov 9, 2026. Shares held after the trade: 11,319 (-40.0%).

Value
$8.93M
Shares
17,161
Average price
$520.13
Role
EVP and CFO
Holding change
-40.0%
Trade date
Nov 6, 2026 to Nov 9, 2026
4:28 PM ET 8-K12B
Other 8-K Filing Texas Pacific Land Corp TPL

Texas Pacific Land Other 8-K Filing

Texas Pacific Land Corporation is completing a redomestication from Delaware to Texas, effective November 17, 2026. The conversion will not change the company's name, management, or business operations, and each share of Delaware common stock will automatically convert into one share of Texas common stock. The move was approved by stockholders at the 2026 Annual Meeting.

4:28 PM ET 8-K
Financial Results Inhibikase Therapeutics, Inc. IKT

Inhibikase Therapeutics Financial Results

Inhibikase Therapeutics reported financial results for the third quarter of 2026, highlighting the expansion of its Phase 3 IMPROVE-PAH study for IKT-001 with 28 country regulatory approvals and 79 clinical sites activated. The company noted it is well-capitalized following a $50 million equity sale to RA Capital in July 2026, which will support the advancement of its PAH clinical program.

Term
Q3 2026

“During our third quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries.”

Mark Iwicki, Chief Executive Officer of Inhibikase

“Supported by the $50 million proceeds from the sale of shares to RA Capital in July, Inhibikase is well-positioned to advance IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population.”

Mark Iwicki, Chief Executive Officer of Inhibikase
4:28 PM ET 10-Q
Financial Results Finwise Bancorp FINW

Finwise Bancorp Q3 2026 Results: Net Income $10M, Up 105.4% YoY

FinWise Bancorp reported total assets of $83.8 million in interest-bearing deposits as of September 30, 2026, a decrease from $151.3 million at year-end 2025. The company is focusing on its Banking-as-a-Service (BaaS) expansion and the integration of its recent acquisition of Tallied Technologies, Inc. to optimize its technology platform.

Key figure
Net income $10M · +105.4% YoY
4:28 PM ET 8-K
Financial Results Biomea Fusion, Inc. BMEA

Biomea Fusion Financial Results

Biomea Fusion reported financial results for the third quarter of 2026, highlighting the completion of enrollment in its Phase II COVALENT-211 trial for icovamenib in type 2 diabetes. The company also reported positive Phase I results for its oral GLP-1 RA candidate, BMF-650, and projected its cash runway into the second quarter of 2027.

Term
Q3 2026

“The third quarter was marked by meaningful execution across both of our clinical programs. We completed enrollment in our first diabetes Phase II clinical trial, COVALENT-211, and continue to advance enrollment in our Phase II COVALENT-212 clinical trial, bringing us closer to important Phase II data readouts for icovamenib in two distinct diabetes populations that we estimate represent over 30% of treated patients with diabetes in the U.S.”

Mick Hitchcock, Ph.D., Interim Chief Executive Officer

“We also reported first-in-human results for BMF-650, providing initial clinical support for our design hypothesis, in that BMF-650 achieved meaningful weight reduction while limited GI side effects were observed, all of which were Grade 1 AEs at the highest dose level.”

Mick Hitchcock, Ph.D., Interim Chief Executive Officer
4:27 PM ET Form 4
Insider Selling Teradata Corp TDC

Teradata President and CEO Stephen Mcmillan Sells $325K of Stock

Stephen Mcmillan, President and CEO, sold 10,000 shares of Teradata Corp at $32.51 a share, worth $325K in total on Nov 9, 2026. Shares held after the trade: 742,446 (-1.3%).

Value
$325K
Shares
10,000
Price
$32.51
Role
President and CEO
Holding change
-1.3%
Trade date
Nov 9, 2026
4:27 PM ET 8-K
Reverse Stock Split Air Industries Group AIRI

Air Industries Group Reverse Stock Split

Air Industries Group announced a 1-for-5 reverse stock split of its common stock, effective November 20, 2026. The split is intended to raise the share price above the $4.00 minimum required for initial listing on the NYSE American following its pending merger with Tenax Aerospace. The consolidation will reduce outstanding shares from approximately 4.86 million to 0.97 million.

4:27 PM ET 8-K/A
Leadership Change AGNT, Inc. AGNT

AGNT Leadership Change

AGNT, Inc. appointed Leo Pareja as Chief Executive Officer, effective October 8, 2026, succeeding Glenn Sanford who transitioned out of the CEO role to facilitate a planned leadership succession. Mr. Pareja previously served as CEO of the company's subsidiary, eXp Realty. This amendment (8-K/A) corrects the description of equity award vesting terms for Mr. Pareja in the event of a qualifying termination following a change in control.

4:27 PM ET 8-K
Capital Raise Benchmark 2026-B44 Mortgage Trust

Benchmark 2026-B44 Mortgage Trust Capital Raise of $777M

Benchmark 2026-B44 Mortgage Trust entered into agreements to sell $701.9 million of publicly offered certificates and $74.8 million of privately offered certificates to a group of underwriters and initial purchasers. The transaction involves the issuance of commercial mortgage pass-through certificates secured by a pool of mortgage loans, with a closing date expected on or about November 20, 2026.

Value
$777M
Counterparty
Goldman Sachs & Co. LLC
4:27 PM ET Form 4
Insider Selling Ceribell, Inc. CBLL

Ceribell Director Joseph Michael Taylor Sells $278K of Stock

Joseph Michael Taylor, Director, sold 10,200 shares of Ceribell, Inc. at $27.22 a share, worth $278K in total on Nov 9, 2026. Shares held after the trade: 38,278 (-21.0%).

Value
$278K
Shares
10,200
Price
$27.22
Role
Director
Holding change
-21.0%
Trade date
Nov 9, 2026
4:26 PM ET Form 4
Insider Selling Motorola Solutions, Inc. MSI

Motorola Solutions Chairman and CEO Gregory Q. Brown Sells $36.4M of Stock

Gregory Q. Brown, Chairman and CEO, sold 70,780 shares of Motorola Solutions, Inc. at $508.81 to $516.89 a share (average $514.14) in 10 transactions, worth $36.4M in total on Nov 6, 2026. Shares held after the trade: 66,769 (-1.0%).

Value
$36.4M
Shares
70,780
Average price
$514.14
Role
Chairman and CEO
Holding change
-1.0%
Trade date
Nov 6, 2026
4:26 PM ET 10-Q
Financial Results NextCure, Inc. NXTC

NextCure Q3 2026 Results: Net Loss of $6.85M, Loss Narrows

NextCure reported a net loss of $31.5 million for the nine months ended September 30, 2026, an improvement from the $46.4 million loss in the prior year period. The company's cash position decreased significantly to $8.7 million as it underwent restructuring and asset impairment charges totaling $3.0 million.

Key figure
Net loss $6.85M
4:26 PM ET 10-K
Financial Results E-Smart Corp. ESMR

E-Smart FY 2026 Results: Net Loss of $128K, Loss Widens

E-Smart Corp. reported a net loss of $127,976 for the fiscal year ended August 31, 2026, compared to a loss of $68,034 in 2025, driven by a significant increase in general and administrative expenses. The company's independent auditor issued a going concern warning due to an accumulated deficit of $238,225 and recurring negative cash flows from operations.

Key figure
Net loss $128K
4:26 PM ET 8-K
Financial Results Big Sky Industrial Inc. BSIN

Big Sky Industrial Financial Results

Big Sky Industrial reported Q3 2026 financial results and provided a construction update on its flagship Big Sky Carbon Hub project in Montana. The company confirmed that Phase 1 fabrication is underway with first production targeted for spring 2027, supported by a five-year, 100% take-or-pay helium offtake agreement.

“The third quarter was about execution, and we are pleased with where the project stands. Our in-field gathering and injection lines are complete, and our long-lead equipment has been procured, including the natural gas-fired generators that will power the plant. Plant fabrication is underway, on-site civil work begins in the coming weeks, and construction remains on schedule.”

Ryan Smith, President and Chief Executive Officer

“We are targeting first production in spring 2027, a window that leaves sensible room for commissioning and the Montana winter. From day one, our helium is sold under a five-year, 100% take-or-pay contract. In October, the Department of Energy designated helium a critical material, which underscores the value of the domestic supply we are building in Montana.”

Ryan Smith, President and Chief Executive Officer
4:25 PM ET 8-K
M&A Deal Archrock, Inc. AROC

Archrock Signs $450M M&A Deal with HiVolt Energy Holdings, LLC

Archrock, Inc. has entered into a definitive agreement to acquire HiVolt Energy Holdings, LLC for an aggregate value of up to $450 million, consisting of $415 million in cash at closing and $35 million in potential earnout incentives. The acquisition integrates HiVolt's prime power microgrid infrastructure with Archrock's natural gas compression business to expand its energy infrastructure offerings. The transaction is expected to close in the first quarter of 2027, subject to regulatory approvals and customary closing conditions.

Value
$450M
Counterparty
HiVolt Energy Holdings, LLC

“Combining HiVolt’s proven prime power microgrid platform with Archrock's natural gas compression offerings will transform our company into a broader provider of energy infrastructure.”

Brad Childers, President and Chief Executive Officer of Archrock

“HiVolt has built a proven, differentiated platform in the energy microgrid market that complements our core compression business and will enable us to provide additional essential services to customers across the energy value chain, particularly in power-constrained geographies.”

Brad Childers, President and Chief Executive Officer of Archrock
4:25 PM ET 8-K
Financial Results StubHub Holdings, Inc. STUB

StubHub Holdings Financial Results

StubHub reported Q3 2026 financial results with revenue increasing 7% year-over-year to $502 million and Gross Merchandise Sales (GMS) reaching $2.6 billion. The company also announced a leadership transition, appointing Michael Noonan as CFO to succeed Connie James effective January 4, 2027. Based on strong performance, StubHub raised its full-year 2026 GMS outlook to a range of $10.175 billion to $10.375 billion.

Term
Q3 2026

“Consumers continue to prioritize live events and value the trusted experience that StubHub provides as the global market leader. We are increasing our full-year GMS outlook to reflect our positive third quarter results and anticipated performance for the remainder of the year. Moving forward, we remain committed to advancing StubHub’s strategic priorities that expand access and choice for fans.”

Eric Baker, Founder, Chairman and Chief Executive Officer
4:24 PM ET 10-Q
Financial Results Lightpath Technologies Inc LPTH

Lightpath Technologies Q1 2026 Results: Net Loss of $1.7M, Loss Narrows

LightPath Technologies reported revenue of $20.8 million for the quarter ended September 30, 2026, a 38% increase compared to the prior year. Despite the revenue growth, the company recorded a net loss of $1.7 million, driven by significantly higher operating expenses in selling, general, and administrative costs and new product development.

Key figure
Net loss $1.7M
4:24 PM ET 8-K
Loan & Debt Akamai Technologies Inc AKAM

Akamai Technologies $2.2B Debt Financing

Akamai Technologies priced a private offering of $2.2 billion in aggregate principal amount of 1.00% convertible senior notes, split equally between tranches due in 2028 and 2031. The company also granted initial purchasers an option to buy up to an additional $300 million in notes. The proceeds are intended for general corporate purposes, including potential debt refinancing or share repurchases.

Value
$2.2B
Term
through Nov 2031
4:24 PM ET 8-K
Financial Results Sonos Inc SONO

Sonos Financial Results

Sonos reported fiscal year 2026 revenue growth of 7% to $1.55 billion and a 39% increase in Adjusted EBITDA to $184 million. Alongside the results, the company announced that its Board of Directors authorized a new $150 million common stock repurchase program following the completion of its previous buyback program.

“We said Fiscal 2026 would be the year Sonos returned to growth, and we delivered. We grew in every region, delivered meaningfully higher profitability, and brought five new products to market. Underneath it all, the system strategy is working - every product improves those our customers already own, and with Sonos 27, that will keep getting stronger every year.”

Tom Conrad, Chief Executive Officer of Sonos

“Fiscal 2026 demonstrated how much the earning power of Sonos has structurally improved. We grew revenue 7%, reduced Non-GAAP operating expenses 3% and grew Adjusted EBITDA 39% to $184 million, all while absorbing $56 million of higher memory costs. That’s the foundation we’re building on, and we’re actively managing the levers available to us to optimize our financial performance.”

Saori Casey, Chief Financial Officer of Sonos
4:24 PM ET 8-K
Financial Results Context Therapeutics Inc. CNTX

Context Therapeutics Financial Results

Context Therapeutics reported Q3 2026 financial results and provided a clinical update on its CTIM-76 program, which showed a 22% confirmed ORR and 5.6 months median PFS in platinum-resistant ovarian cancer. The company ended the quarter with $34.4 million in cash, providing a runway into Q4 2027.

Term
Q3 2026

“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy. Our Phase 1b strategy is to evaluate CTIM-76 in patients with no more than five prior lines of therapy. These less heavily pretreated patients generally have lower tumor burden and better T cell fitness, providing a rationale to evaluate whether treatment in this population, together with Q3W dosing, can deliver greater clinical benefit and improved tolerability.”

Martin Lehr, Chief Executive Officer
4:23 PM ET 8-K
M&A Deal Centerspace CSR

Centerspace M&A Deal with Independence Realty Trust, Inc.

Centerspace shareholders and Independence Realty Trust (IRT) stockholders approved the previously announced merger between the two multifamily REITs. Upon closing, Centerspace shareholders will receive 3.800 shares of IRT common stock for each share owned. The deal remains subject to remaining closing conditions, including lender consents for certain mortgage loans.

Counterparty
Independence Realty Trust, Inc.
4:23 PM ET 8-K
Financial Results Palisade Bio, Inc. PALI

Palisade Bio Financial Results

Palisade Bio reported third quarter 2026 financial results and provided a clinical update on its PALI-2108 programs, including the initiation of the Phase 2b ASCENTRA-UC trial. The company ended the quarter with $113.6 million in cash and expects topline results from the UC trial in Q4 2027.

“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress.”

JD Finley, Chief Executive Officer of Palisade Bio

“In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”

JD Finley, Chief Executive Officer of Palisade Bio
4:23 PM ET 8-K
Capital Raise Hyundai Auto Receivables Trust 2026-D

Hyundai Auto Receivables Trust 2026-D Capital Raise

Hyundai Auto Receivables Trust 2026-D completed the issuance and sale of several classes of asset-backed notes on November 10, 2026. The transaction involved the transfer of retail installment sale contracts for automobiles from Hyundai Capital America to the trust vehicle. This filing formalizes the definitive agreements, including the Indenture and Sale and Servicing Agreement, related to the securitization.

4:22 PM ET 8-K
Capital Raise Hagerty, Inc. HGTY

Hagerty Capital Raise

Hagerty announced the commencement of an underwritten secondary public offering of 9,000,000 shares of its Class A common stock by Hagerty Holding Corp. The selling stockholder also intends to grant underwriters a 30-day option to purchase up to an additional 1,350,000 shares. Hagerty will not receive any proceeds from the sale, as the net proceeds will be used by the selling stockholder to redeem shares for the benefit of the Kim Hagerty Revocable Trust.

Counterparty
Hagerty Holding Corp.
4:22 PM ET 8-K
Financial Results Seer, Inc. SEER

Seer Financial Results

Seer, Inc. reported third quarter 2026 revenue of $4.0 million, a sequential increase from $3.1 million in Q2 2026, driven by consumable purchases from established customers and new pharmaceutical platform adoptions. The company ended the quarter with $198.1 million in cash and updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million.

Term
Q3 2026

“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform.”

Omid Farokhzad, Chair and Chief Executive Officer

“Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use. With a strong balance sheet and growing evidence of the platform’s value, I remain confident in Seer’s opportunity and committed to building long-term value for our shareholders.”

Omid Farokhzad, Chair and Chief Executive Officer
4:22 PM ET 8-K
Financial Results Swarmer, Inc SWMR

Swarmer Financial Results

Swarmer, Inc. reported Q3 2026 financial results, highlighting its transition from a software provider to an integrated defense solutions supplier. The company is nearing the close of its acquisition of Ratel Robotics and announced a pending IP acquisition from Vataga Drone to bolster its hardware capabilities. Reported revenue for the quarter was $25,554, primarily from support services, as the pending Ratel acquisition's performance is not yet consolidated.

Term
Q3 2026

“The third quarter marked a pivotal period for Swarmer as we made meaningful progress toward our vision of bringing combat-tested technologies from Ukraine to allied nations.”

Alex Fink, Swarmer’s President and U.S. CEO

“Ground vehicles, air defense and integrated autonomous drone kits represent the three pillars of our expanding market position.”

Alex Fink, Swarmer’s President and U.S. CEO
4:22 PM ET 8-K
Stock Plan Amendment Price T Rowe Group Inc TROW

Price T Rowe Group Stock Plan Amendment

T. Rowe Price Group amended its 2020 Long-Term Incentive Plan and related grant notices to modify vesting provisions. The changes allow for the continued vesting of equity awards for employees following certain involuntary terminations and introduce new vesting terms for future grants.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.